Pascual-Pasto et al. showcased an in vitro model where T-cells could be engineered to express a GPC2 CAR using a lentiviral vector and secrete a bispecific innate immune cell engager (or BiCE) that targets GD2 and FcγRIIIa (or CD16a) to activate bystander NK-cells and macrophages in the TME to facilitate antitumor innate immunity in neuroblastoma (77). This evidence concerns the gene FCGR3A and neuroblastoma.